Faculty

Jill R Glausier, PhD

Jill R Glausier, PhD

Assistant Professor of Psychiatry

Contact Details

3811 O'Hara Street
Pittsburgh
 
PA
 
15213
Email
Website
Translational Neuroscience Program
NIH NeuroBioBank

Education & Training

PhD
Neuroscience, Emory University
Neuroscience, University of Pittsburgh

Professional Affiliations

Member, Society for Neuroscience
Member, Society of Biological Psychiatry
Member, Schizophrenia International Research Society

Selected Honors & Awards

NARSAD Young Investigator Award, Brain & Behavior Research Foundation
Hamilton Family Award for Basic Neuroscience Research in Psychiatry,

Research Interests

Postmortem human brain tissue research; Schizophrenia; Cortical circuitry & mitochondrial alterations
Selected Research Publications & Products
  1. Xue X, Zong W, Glausier JR, Kim SM, Shelton MA, Phan BN, Srinivasan C, Pfenning AR, Tseng GC, Lewis DA, Seney ML, Logan RW (2022). Molecular rhythm alterations in prefrontal cortex and nucleus accumbens associated with opioid use. Transl Psychiatry, 12(1).
  2. Glausier JR*, Datta D*, Fish KN, Chung DW, Melchitzky DS, Lewis DA (2021). Laminar differences in the targeting of dendritic spines by cortical pyramidal neurons and interneurons in human dorsolateral prefrontal cortex. Neuroscience, 452: 181-191.*Authors contributed equally to this work.
  3. Glausier JR, Enwright JF 3rd, Lewis DA (2020). Diagnosis- and cell type-specific mitochondrial functional pathway signatures in schizophrenia and bipolar disorder. Am J Psychiatry, 177(12): 1140-1150.Featured in The American Journal of Psychiatry Articles of Import and Impact 2020 with accompanying editorial.
  4. Glausier JR, Kelly MA, Salem S, Chen K, Lewis DA (2020). Proxy measures of premortem cognitive aptitude in postmortem subjects with schizophrenia. Psychol Med, 50(3): 507-514.
  5. Glausier JR, Roberts RC, Lewis DA (2017). Ultrastructural analysis of parvalbumin synapses in human dorsolateral prefrontal cortex. J Comp Neurol. 525(9):2075-2089.

Biological Psychiatry: Diurnal Alterations in Gene Expression Across Striatal Subregions in Psychosis

Drs. Kyle Ketchesin & Colleen McClung

Psychosis, an impairment that manifests as hallucinations and/or delusions, is a defining feature of schizophrenia and highly prevalent in bipolar disorder. Individuals suffering with these illnesses also have major disruptions in sleep and circadian rhythms, which can precipitate or exacerbate psychotic symptoms. A group of investigators including Kyle Ketchesin, PhD (Assistant Professor of Psychiatry), Madeline...

The American Journal of Psychiatry: Diagnosis- and Cell Type-Specific Mitochondrial Functional Pathway Signatures in Schizophrenia and Bipolar Disorder

Glausier et al AJP 2021

Schizophrenia and bipolar disorder share genetic and environmental risk factors, and in some cases, certain clinical features such as cognitive impairments and psychosis. Mitochondrial dysfunction is proposed to contribute to the functional, morphological, and molecular brain alterations that may underlie the common features of these disorders. However, mitochondria are critical for multiple biological processes...

Now in JAMA Psychiatry: Synaptic Proteome Alterations in the Primary Auditory Cortex of Individuals with Schizophrenia

Individuals with schizophrenia often exhibit impairments in the processing of auditory sensory information and auditory learning. Previous research has implicated the involvement of synaptic protein networks in the pathology of schizophrenia. The number, type and strength of connections between synapses are governed in large part by complex protein networks. “In order for the synapse to function, many different...

Now in Molecular Psychiatry: Department Investigators Uncover Molecular Alterations in Obsessive-Compulsive Disorder

Dr. Susanne Ahmari

Obsessive-compulsive disorder (OCD) is a disabling illness characterized by obsessions that result in compulsive behavior. Underscoring the need for more effective treatments, existing first-line therapies lead to remission in just 10–15% of patients. However, the development of new therapies requires a better understanding of the molecular abnormalities that are present in OCD. A recent study from Pitt Department...